Babesia microti Protein BmSP44 Is a Novel Protective Antigen in a Mouse Model of Babesiosis

Hui Wang,Yao Wang,Jilei Huang,Bin Xu,Junhu Chen,Jianfeng Dai,Xia Zhou
DOI: https://doi.org/10.3389/fimmu.2020.01437
IF: 7.3
2020-07-07
Frontiers in Immunology
Abstract:Babesiosis caused by <i>Babesia</i> species imposes an increasing threat to public-health and so far, there is no effective vaccine to prevent <i>Babesia</i> infections. <i>Babesia</i> surface antigen may participate in the invasion of erythrocytes. In our previous study, a surface antigen of <i>B. microti</i> merozoites, named as <i>Bm</i>SP44 was identified as a dominant reactive antigen by protein microarray screening. To evaluate its potential applications in diagnosis and prevention of Babesiosis, the open reading frame encoding <i>Bm</i>SP44 was cloned and the recombinant protein was expressed. In consistent with the protein microarray result, recombinant <i>Bm</i>SP44 (r<i>Bm</i>SP44) can be recognized by sera from <i>B. microti</i> infected mice. Immunofluorescence assays (IFA) confirmed that <i>Bm</i>SP44 is a secreted protein and localized principally in the cytoplasm of the parasites. The parasitemia and <i>Babesia</i> gene copies were lower in mice administered r<i>Bm</i>SP44 antisera compared with normal controls. Active immunization with r<i>Bm</i>SP44 also afforded protection against <i>B. microti</i> infection. The concentrations of hemoglobin in r<i>Bm</i>SP44 immunization group were higher than those in the control group. Importantly, vaccination of mice with r<i>Bm</i>SP44 resulted in a Th1/Th2 mixed immune response with significantly elevated IL-10 and IFN-γ levels during the early stage of infection. Taken together, our results indicated that r<i>Bm</i>SP44 can induce a protective immune response against <i>Babesia</i> infection. Thus, <i>Bm</i>SP44 can be used as both a diagnosis marker and a vaccine candidate.
immunology
What problem does this paper attempt to address?